Dr. Andrew Seidman is an Attending Physician for the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Professor of Medicine at Weill Cornell Medical College. Dr. Seidman earned his medical degree from Hahnemann University School of Medicine in Philadelphia, Pennsylvania in 1985. He completed a residency in Internal Medicine at the Pennsylvania Hospital. Dr. Seidman then completed a fellowship in Medical Oncology and Hematology at Memorial Sloan Kettering Cancer Center in New York.
Dr. Seidman's clinical research in the development of taxanes for breast cancer has impacted clinical care worldwide. He has authored or co-authored more than 200 peer-reviewed articles, reviews and book chapters, as well as over 160 abstracts, has served on the editorial boards of over a dozen leading oncology journals, and has lectured at innumerable national and international conferences and symposia on breast cancer related topics. Dr. Seidman is a Past-President of the American Society of Breast Disease, and the recipient of a Career Development Award from the American Society of Clinical Oncology (ASCO) for his work developing taxanes for breast cancer. He has received the Gay Clark Stoddard Award from the Susan G. Komen Foundation for excellent and compassionate care of patients with breast cancer, the Jacob Ehrenzeller Award from Pennsylvania Hospital for Academic Excellence and a Distinguished Alumnus Award from the Hahnemann University School of Medicine. He chaired a Working Group for the National Cancer Institute's Breast Cancer Steering Committee on Meaningful and Appropriate Endpoints for Clinical Trials in Metastatic Breast Cancer (J Clin Oncol 2018).
He serves on the ASCO Communications and Education Committees. At MSK, he has served as Associate Chair of Academic Administration, Medical Director of the Bobst International Center, and Senior Breast Cancer Advisor to the MSKCC-IBM Watson Collaboration. Dr. Seidman has served on the Oncology Drug Advisory Committee to the U.S. Food and Drug Administration. He currently leads an active translational research program focused on novel systemic treatment strategies for breast cancer brain metastases.